CD9 and breast carcinoma: After preliminary experiments, in which silencing CD9 or CD81 alone in MDA-MB-231 breast cancer cells produced only modest phenotypic changes (Fig. S1), we established cells with stable silencing of both tetraspanins (CD9/81si cells).